MacroGenics Inc. (MGNX)
NASDAQ: MGNXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MGNX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $125.26M
- EPS (TTM)
- -$2.30
- Dividend yield
- None
- 52-week range
- 1.32 – 5.08
- Day range
- 1.90 – 2.08
- Volume / Avg
- 1.52M / 747.02K
- Beta
- —
- Shares outstanding
- 63.91M
52-week range
MGNX stock today
Shares of MacroGenics (MGNX) finished lower on Nov 20 at $1.96, a drop of 1.01% or $0.02 per share, versus the S&P 500's 3.70% decline. Volume was 2.0x the average at 1.52M shares, a sign of unusually heavy trading. At this level, MGNX sits near the bottom of its 52-week range of $1.32 to $5.08: 61.4% below the high, set on Jun 24, 2026 and 48.5% above the low.
MGNX is up 21.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 40.0%. MacroGenics has posted a net loss over the last twelve months (EPS of -$2.30), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MacroGenics
Company profileMacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Eric Blasius Risser
- Headquarters
- Rockville, MD
- Employees
- 293
- IPO year
- 2013
- Website
- macrogenics.com
Financial highlights
Full financialsIn fiscal 2025, MacroGenics generated $149.5 million in revenue, down 0.3% from fiscal 2024, its first annual decline since 2023. MacroGenics reported a net loss of $74.6 million, compared with a loss of $67.0 million a year earlier. Gross margin was 100.0% (up from 99.4%) and operating margin -48.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $149.50M | $149.96M | $58.75M | $151.94M | $77.45M |
| Growth | -0.31% | +155.26% | -61.33% | +96.19% | -26.16% |
| Net income | $-74.62M | $-66.97M | $-9.06M | $-119.76M | $-202.12M |
| EPS (diluted) | $-1.18 | $-1.07 | $-0.15 | $-1.95 | $-3.37 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$8.00+308.16%
- Strong buy 1
- Buy 2
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.34 vs $-0.10
- Surprise
- -240.00%
MGNX news
All MGNX news- MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue EstimatesNasdaqMGNX, MDT
- MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate ProgressGlobeNewswire
- MacroGenics, Inc. Appoints Michael Vasconcelles and Emil Kuriakose to Board of DirectorsNasdaq
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike DealsNasdaqAARD, ABBV, ARTV, AZN
- ResMed (RMD) Beats Q1 Earnings and Revenue EstimatesNasdaqRMD, MGNX
- MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic CancerGlobeNewswire
- MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHNGlobeNewswire
MacroGenics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SIONSionna Therapeutics Inc. | 2.83 | -4.88% | $127.79M | vs MGNX |
| MSLESatellos Bioscience Inc. | 5.68 | -2.07% | $120.51M | vs MGNX |
| ZNTLZentalis Pharmaceuticals Inc. | 1.36 | 0.00% | $133.64M | vs MGNX |
| ADAGAdagene Inc. ADR | 1.76 | -12.44% | $118.17M | vs MGNX |
| ALXOALX Oncology Holdings Inc. | 1.06 | +3.92% | $137.03M | vs MGNX |
| OKUROnKure Therapeutics Inc. Class A | 2.70 | -2.17% | $111.21M | vs MGNX |
| IMUXImmunic Inc. | 6.99 | -5.41% | $111.01M | vs MGNX |
| MENSJyong Biotech Ltd. | 1.45 | -17.14% | $110.24M | vs MGNX |
Indexes, lists and sector
MacroGenics stock FAQ
What is MacroGenics's stock price today?
MGNX last traded at $1.96 as of Nov 20, 4:00 PM EST, down 1.01% on the day. Prices are delayed at least 15 minutes.
Who is MacroGenics's CEO?
Mr. Eric Blasius Risser is the chief executive officer of MacroGenics Inc., which has about 293 employees.
What is the MGNX 52-week high?
The 52-week high for MGNX is $5.08 and the 52-week low is $1.32. The stock is currently 61.4% below its high.